Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -
Covered in this story
Call it yourself
No calls on $SLDB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Solid Biosciences Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.